Deborah T.
- Country
- France
- Department
- Anesthésie
Research Overview
Data & Insights
Has run more than one trial at 0 of 6 partner sites.
Specializations
Hematologic Malignancies
The investigator concentrates on high‑risk Acute Myeloid Leukemia and related myeloid disorders, including Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, and Acute Lymphoblastic Leukemia, with an emphasis on relapsed or refractory disease.
- Relapsed/Refractory AML
- High‑risk MDS/CMML
- ALL in younger adults
- Acute graft‑versus‑host disease
Research aims to integrate novel targeted agents for patients lacking standard therapeutic options.
MTAP‑Deleted Solid Tumors
Focused investigations target tumors harboring homozygous MTAP deletions, spanning diverse histologies such as non‑small cell lung cancer, mesothelioma, sarcoma, pancreatic ductal adenocarcinoma and glioblastoma.
- MTAP‑deleted NSCLC (squamous and nonsquamous)
- MTAP‑null mesothelioma
- MTAP‑deficient sarcoma
- MTAP‑deleted pancreatic adenocarcinoma
- MTAP‑negative glioblastoma
Efforts prioritize biomarker‑driven therapies for patients with limited treatment alternatives.
Gynecologic Oncology
The program includes a broad spectrum of female reproductive tract cancers, emphasizing advanced and recurrent disease states such as Anal Squamous Cell Carcinoma, Endometrial Carcinoma, Cervical Squamous Cell Carcinoma, and Vulvar Squamous Cell Carcinoma.
- Advanced endometrial carcinoma
- Recurrent cervical cancer
- Metastatic vulvar SCC
- Anal SCC with high‑risk features
Clinical focus is on integrating immunotherapy and targeted agents for tumors resistant to conventional regimens.
Thoracic and Head‑Neck Cancers
Investigations cover malignant diseases of the thorax and upper aerodigestive tract, including Non‑Small Cell Lung Cancer, Small Cell Lung Carcinoma, Mesothelioma, and Head and Neck Squamous Cell Carcinoma, with particular attention to metastatic and unresectable presentations.
- ALK‑positive NSCLC
- EGFR‑mutated NSCLC
- Advanced mesothelioma
- Recurrent HNSCC
- Limited‑stage SCLC
Therapeutic strategies explore combination immuno‑oncology and molecularly targeted approaches.
Hepatobiliary & Pancreatic Oncology
Key interests include malignancies of the liver, bile ducts and pancreas, such as Biliary Adenocarcinoma, Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma, and Hepatocellular Carcinoma, particularly in advanced or unresectable stages.
- Advanced cholangiocarcinoma
- Metastatic pancreatic adenocarcinoma
- Unresectable hepatocellular carcinoma
- Biliary tract cancer
Research seeks to evaluate novel agents and combination regimens for patients with poor prognosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.